[Accelerated streptokinase dose regimens for coronary thrombolysis]

Area of Science:

• Cardiology
• Pharmacology

Context:

• Acute myocardial infarction (AMI) remains a leading cause of mortality worldwide.
• Timely reperfusion of infarct-related arteries is critical for improving outcomes in AMI patients.
• Intravenous thrombolysis is a key treatment strategy for AMI.

Purpose:

• To evaluate the efficacy and safety of an accelerated intravenous streptokinase dose regimen in patients with acute myocardial infarction.
• To assess the impact of treatment timing on reperfusion rates.

Summary:

• Forty patients with acute myocardial infarction received accelerated intravenous streptokinase (1.5 million U/30 min) within 12 hours of symptom onset.
• Overall reperfusion rate was 77.5%. Patients treated within 6 hours had a significantly higher reperfusion rate (89.3%) compared to those treated between 6-12 hours (50%).
• Mild bleeding complications occurred in 12.5% of patients; hypotension and chills were infrequent. The 5-week mortality rate was 2.5%.

Impact:

• The accelerated intravenous streptokinase regimen appears to be an effective strategy for achieving coronary thrombolysis in acute myocardial infarction.
• Early administration of streptokinase (within 6 hours) is associated with superior reperfusion outcomes.
• The treatment demonstrates a promising safety profile, with low rates of severe adverse events, supporting its clinical utility.